<image>

Implementation of COVID-19 VE studies

5.1.2e 5.1.2e

Kick off meeting COVID-19 VE studies with Member States, 15 January 2020

15.01.2021

Background to the project



Surveillance of Severe Acute Respiratory Infections

Multi centre EU/EEA vaccine effectiveness studies IMOVE SpidNet PERTINENT



Objectives of the project



To support ECDC in the assessment of effectiveness of vaccines against COVID-19

To support ECDC in laying the ground to set up an infrastructure for studies on COVID-19 vaccine effectiveness

Frequent reporting to ECDC



Overview of activities ("lots") within the project



"Methodological" expert virtual meetings Coordination ECDC - Epiconcept

Vaccine effectiveness study with a hospital based system EU/EEA study protocol study implementation

Vaccine effectiveness study in health care workers EU/EEA study protocol study implementation

Letter of interest dated 23 December 2020 from ECDC to NC referred to the two studies above



Overview of activities ("lots") within the project



Vaccine effectiveness study in Long Term Care Facilities study protocol

Vaccine effectiveness study in outpatients mapping current practices study protocol

Vaccine effectiveness study in another setting study protocol



Recruitment of countries and sites, method



Letter from ECDC Director to National Coordinators asking on expression of interest to take part to one or both studies

One point of entrance which can allow overview from national level

No need to have a systems in place, but commitment to invest in progressively implementing a common protocol



Recruitment of sites, criteria considered




- EU/EEA geographic representation
- High sample size
- Possibility to implement high quality and validated data on vac. Status
- Access to validated laboratory testing
- Previous experience with SARI surveillance (hosp study)
- Previous established cohort of hcw (hcw study)
- Ability to recruit and follow up HCW with regular testing / households members (hcw study)
- Possibility to implement immunogenicity profiles in a subset of the cohort (hcw study)

Main criteria noted in the letter presented above



Countries expressing interest in ECDC VE studies





Countries expressing interest in ECDC VE studies

Countries	SARI VE Study	VE in HCWs	General Interest
Belgium	Х		
Bulgaria			Х
Czechia			Х
Finland			Х
France	Х	?	
Germany	Х		
Greece			Х
Ireland			Х
Luxembourg			Х
Malta	Х		
Netherlands	Х	Х	
Norway			Х
Poland			Х
Portugal			Х
Spain			Х

9

ecoc

Recruitment of countries and sites, method



ECDC work closely with Epiconcept

Epiconcept will further contact countries to understand the characteristics of your sites/hospitals/cohort will propose a final list to ECDC

